Abstract
Currently, pharmacotherapy of coronary heart disease, based on antianginal drugs directly improve coronary blood flow, antiplatelet, and lipid-lowering drugs, includes a new class of drugs - cardiocytoprotectors. Recent ischemic cardiomyocytes improve security in the ATP, by optimizing the energy metabolism by reducing the need for oxygen cardiomyocytes and has an antioxidant effect, protecting cellular structures and enzymes from oxidative stress accompanying hypoxia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
